SecBot SecBot
SECBOTREPLAY Home › Report › PVLA

PVLA · Palvella Therapeutics held its 2026 Annual Meeting on June 10, 2026,…

PALVELLA THERAPEUTICS, INC. · 8-K filed Jun 16, 2026 at 08:30 ET

At the news

NEUTRALIMPACT 2/10

8-K filed Jun 16, 2026 at 08:30 ET

Palvella Therapeutics held its 2026 Annual Meeting on June 10, 2026, where shareholders approved an amendment to the 2024 Equity Incentive Plan to increase authorized shares by 750,000 (approximately 5.2% of outstanding shares). All director nominees were elected, Ernst & Young was ratified as auditor, and advisory votes on executive compensation and frequency were approved. This is a routine governance filing with no material financial or operational impact.

  • Shareholders approved an amendment to the 2024 Equity Incentive Plan, increasing authorized shares by 750,000.
  • Class III directors George M. Jenkins, Todd C. Davis, and John Doux, M.D. were elected with strong support.
  • Ernst & Young LLP was ratified as independent auditor for fiscal 2026 with 11,557,687 votes for.
  • Advisory vote on named executive officer compensation passed with 10,008,180 votes for.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access